Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ortetamine SCHEMBL209899 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL29388899 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27660676 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL3460028 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL16737004 | 0.98 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL744048 | 0.98 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL4381142 | 0.90 | SLC6A4 (0.70) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL2857779 | 0.85 | SLC6A2 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27703116 | 0.83 | CYP2D6 (0.44) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL727640 | 0.83 | SOS2 (0.53) | TAAR1SLC6A2SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-12377065-B2 | Compositions for treatment of substance use disorder | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2025-08-05 | — | — | US | claimed |
| CN-117871845-A | Kit for detecting methyl amphetamine and preparation method thereof | 北京迈康源生物科技有限公司 | 2024-04-12 | — | — | CN | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| CN-116710084-A | Use of mGluR5 antagonists for the treatment of amphetamine addiction | 诺华股份有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116606638-A | Preparation method and application of water-soluble quantum dot | 广纳达康(广州)生物科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20220233479-A1 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2022-07-28 | — | — | US | claimed |
| CN-109752536-B | Optical probe based on gold nanoparticle efficient assembly structure and preparation and application thereof | 浙江工业大学 | 2022-03-15 | — | — | CN | claimed |
| US-20220072311-A1 | TREATMENT OF ADDICTION AND DEPENDENCY | TACA JR ARTURO C (US) | 2022-03-10 | — | — | US | claimed |
| US-11207322-B2 | Method and composition related to combination therapy for addiction | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-28 | — | — | US | claimed |
| CN-1898201-A | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION INC (US) | 2007-01-17 | — | — | CN | claimed |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| CN-1526695-A | Darr reaction process of quinone derivative composition to produce free radical and its application | 山东省生物信息工程技术研究中心 | 2004-09-08 | — | — | CN | claimed |
| CN-1124341-C | Monoclonal antibody specific for methamphetamine, hybridoma producing the same, kit containing the same and use thereof | BIOTECHNOLOGY DEV CT (CN) | 2003-10-15 | — | — | CN | claimed |
| US-6436649-B1 | COMPETITIVE BINDING WITH ANTI-HAPTEN ANTIBODY IN SOLUTION CONTAINING REPORTER MOLECULE SUBSTRATE; ADDING B-LACTAMASE QUANTITATIVE ANALYSIS USING VISIBLE OR ULTRAVIOLET RADIATION | LE REGION WALLONE (BE) | 2002-08-20 | — | — | US | claimed |
| EP-0897540-B1 | METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF | WALLONE REGION (BE) | 2001-07-04 | — | — | EP | claimed |
| WO-1999064861-A2 | METHOD OF IDENTIFYING ANTIDEPRESSANT COMPOUNDS | UNIVERSITY COLLEGE LONDON (GB) | 1999-12-16 | — | — | WO | claimed |
| EP-0897540-A1 | METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF | LA REGION WALLONNE (BE) | 1999-02-24 | — | — | EP | claimed |
| CN-1179469-A | Monoclonal antibody specific for methamphetamine, hybridoma producing the same, kit containing the same and use thereof | BIOTECHNOLOGY DEV CENTER (CN) | 1998-04-22 | — | — | CN | claimed |
| WO-1997041435-A1 | METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF | LA REGION WALLONNE (BE) | 1997-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233479-A1 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | PNMT, METTL3, BHMT2 | TAAR1 124/4885SLC6A2 98/4885SLC6A4 121/4885 |
| US-12377065-B2 | Compositions for treatment of substance use disorder | PNMT, METTL3, BHMT2 | TAAR1 124/4885SLC6A2 98/4885SLC6A4 121/4885 |
| US-20040176378-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system | HTR2C, HTR2A, PTGS2 | TAAR1 72/4885SLC6A2 21/4885SLC6A4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.